Showing results (1151-1160 of 1,274) with videos related to

Sort By:
Pageof 128
Multiple Sclerosis and Related Disorders|May 12, 2026
Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSSElisa Saeedzadeh, Manav V Vyas, Shristi Sharma, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
BMC Medicine|May 2, 2017
Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trialOfra Kalter-Leibovici, Dov Freimark, Laurence S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?A Bar-Or, J Oger, E Gibbs, et al.
Bone Marrow Transplantation|May 4, 2010
Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registriesY C Cohen, A Scaradavou, C E Stevens, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
JAMA Neurology|March 29, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical TrialLudwig Kappos, Robert J Fox, Michel Burcklen, et al.
Bone Marrow Transplantation|January 25, 2011
(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphomaK E Abou-Nassar, K E Stevenson, J H Antin, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Pageof 128